The collaboration aims to create a mouse model that integrates specific POLG mutations—which impair mitochondrial DNA replication—with proteins linked to Parkinson’s disease. Current models often fall short in replicating the clinical realities of these conditions, creating a significant barrier for drug discovery. By combining these genetic markers, researchers hope to establish a more reliable platform for testing therapeutic efficacy.
Mighty Therapeutics Launches POLG Research to Tackle Parkinson’s
Conflict persists in treating neurodegenerative disease because current laboratory mouse models fail to accurately mirror the progression of human mitochondrial disorders. To bridge this gap, Mighty Therapeutics is joining forces with the POLG Foundation and The Jackson Laboratory to develop a sophisticated preclinical model for Parkinson’s and POLG-related conditions.
Dr. Carolyn Sue of Neuroscience Research Australia emphasized that this dual-disease approach is essential for understanding the aging population's neurological health. The effort follows recent clinical signals from Mighty’s research, including positive data from its MMPOWER-3 and NuPOWER studies regarding elamipretide. The company is also evaluating bevemipretide for Parkinson’s, supported by a 2023 grant from the Michael J. Fox Foundation. For families affected by rare POLG disorders, the project offers a pathway to decode the mechanics of mitochondrial dysfunction, which underpins not only rare genetic diseases but also broader neurodegenerative and systemic health challenges.
Comments (0)
No comments yet. Be the first!